GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algorae Pharmaceuticals Ltd (ASX:1AI) » Definitions » Price-to-Funds-From-Operations

Algorae Pharmaceuticals (ASX:1AI) Price-to-Funds-From-Operations : (As of Jun. 08, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Algorae Pharmaceuticals Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Algorae Pharmaceuticals (ASX:1AI) Business Description

Traded in Other Exchanges
Address
201 Sussex Street, Level 16, Tower 2, Darling Park, Sydney, NSW, AUS, 2000
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for undermet medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. Its lead products comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualised to be a potential treatment for dementia, including Alzheimer's disease; NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.